Cryoport(US:CYRX)2022-02-25 00:06Financial Data and Key Metrics Changes - The company reported total revenue of $222.6 million for the full year 2021, representing a 183% year-over-year growth [14] - Organic revenue growth was 34% in Q4 2021, indicating strong performance [14] - The company ended the year with $628 million in cash, cash equivalents, and short-term investments, marking the strongest financial position in its history [13] Business Line Data and Key Metrics Changes - The company onboarded 311 new pharma/biopharma customers during the quarter, contributing to a total of 602 regenerative medicine clinical trials supported, a 14% increase from 2020 [15] - Revenue from commercial agreements increased globally, with commercial biopharma revenue rising by 44% in Q4 [28] - MVE and CRYOPDP experienced mid-20s growth rates year-over-year, with MVE facing a $2 million revenue slippage due to transportation challenges [21][22] Market Data and Key Metrics Changes - The company operates 33 facilities in 15 countries, expanding its geographic footprint to cover key biopharmaceutical regions [18] - The cell and gene therapies market is experiencing rising activity, with 11 Cryoport-supported BLAs or MAAs filed in 2021 and an anticipated 19 filings in 2022 [16][17] Company Strategy and Development Direction - The company aims to sharpen its focus on the cell and gene therapy markets, strengthen its brands, and build market share leadership [20] - The company is actively pursuing M&A opportunities to enhance its capabilities in biostorage, logistics, and software services [43][44] - New initiatives for 2022 include the opening of global bioservices centers and the introduction of the Cryosphere technology [46][49] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply chain challenges but expressed confidence in managing these issues effectively [24] - The company expects continued strong demand in the biopharma market, with a flywheel of clinical trials driving growth [41] - Management reiterated aspirational revenue goals of $650 million to $750 million by 2025 [40] Other Important Information - The company reported a $19 million adjusted EBITDA for the year, compared to breakeven the previous year, indicating improved operational performance [54] - SG&A costs increased due to resource additions for engineering and development work, as well as preparations for launching new bioservices centers [52] Q&A Session Summary Question: Performance of MVE and CRYOPDP - Management confirmed that both MVE and CRYOPDP performed well, with mid-20s growth rates year-over-year, despite a $2 million revenue slippage in Q4 due to transportation delays [21][22] Question: Supply Chain Challenges - Management acknowledged ongoing supply chain issues but stated they are manageable and do not foresee significant disruptions in the future [24][31] Question: Clinical Trial Business and Funding - Activity in clinical trials remains robust, with a record number of trials supported, and companies in the cell and gene space are well-funded [27] Question: Competitive Contract Wins and Market Share - Management believes they will continue to capture market share in the cell and gene therapy space, with minimal impact from COVID trials [30] Question: SG&A Costs Increase - The increase in SG&A costs is attributed to resource additions for engineering and preparations for new bioservices centers [52] Question: Incremental Revenue from Clinical Trials - The company is diversifying revenue streams beyond transportation, leading to increased average spend per clinical trial [58]